Retatrutide, a groundbreaking dual-acting glucose-dependent incretin analog, represents a significant advance in peptide therapeutics for the treatment of type 2 diabetes and, increasingly, excess adiposity. Unlike many existing therapeutic interventions, retatrutide integrates the actions of a GLP-1 receptor activator and a GIP receptor activator,